

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: TMI285439

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>SEQUENCE:</b>	3

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
BioTissue Holdings Inc.	FORMERLY Tissue Tech, Inc.	06/07/2024	Corporation: FLORIDA
BioTissue Ocular Inc.	FORMERLY Bio-Tissue, Inc.	06/07/2024	Corporation: FLORIDA
BioTissue Surgical Inc.	FORMERLY Amniox Medical, Inc.	06/07/2024	Corporation: DELAWARE

## RECEIVING PARTY DATA

<b>Company Name:</b>	U.S. Bank Trust Company, National Association
<b>Street Address:</b>	214 N. Tryon Street, 26th Floor
<b>Internal Address:</b>	Attention: BioTissue Holdings Loan Administrator
<b>City:</b>	Charlotte
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	28202
<b>Entity Type:</b>	Chartered Bank: N/A

## PROPERTY NUMBERS Total: 19

Property Type	Number	Word Mark
Registration Number:	2841984	AMNIOGRAFT
Registration Number:	6777086	AMNIOGRAFT
Registration Number:	4527971	AMNIOGUARD
Registration Number:	3363953	BIOTISSUE
Registration Number:	4515363	CLARIX
Registration Number:	4667121	CORD 1K
Registration Number:	4522781	CRYOTEK
Registration Number:	4205381	NEOX
Registration Number:	3347610	PROKERA
Registration Number:	5556306	REGENESOL
Registration Number:	5481836	RESPINA
Registration Number:	7157931	SHARING MIRACLES
Registration Number:	5360643	STERITEK

CH \$490.00.00 78146610

Property Type	Number	Word Mark
Registration Number:	5917974	TISSUETECH
Registration Number:	4205384	NEOX
Serial Number:	97588024	BIOTISSUE
Serial Number:	98322150	CAM360 AMNIOGRAFT
Serial Number:	90590617	RECRYVIA
Serial Number:	97588029	

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 2026626000

**Email:** akwon@cov.com

**Correspondent Name:** Covington & Burling LLP

**Address Line 1:** ONE CITY CENTER, 850 TENTH ST NW

**Address Line 4:** Washington, DISTRICT OF COLUMBIA 20001

**ATTORNEY DOCKET NUMBER:** 040200.00030

**NAME OF SUBMITTER:** Ashley Kwon

**SIGNATURE:** Ashley Kwon

**DATE SIGNED:** 06/07/2024

**Total Attachments: 26**

- source=BioTissue - IP Security Agreement [Execution Version]#page1.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page2.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page3.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page4.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page5.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page6.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page7.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page8.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page9.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page10.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page11.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page12.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page13.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page14.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page15.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page16.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page17.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page18.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page19.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page20.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page21.tif
- source=BioTissue - IP Security Agreement [Execution Version]#page22.tif

source=BioTissue - IP Security Agreement [Execution Version]#page23.tif

source=BioTissue - IP Security Agreement [Execution Version]#page24.tif

source=BioTissue - IP Security Agreement [Execution Version]#page25.tif

source=BioTissue - IP Security Agreement [Execution Version]#page26.tif

## **INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of June 7, 2024 (as amended, supplemented, amended and restated or otherwise modified from time to time, this “Agreement”), is by and among BioTissue Holdings Inc., a Florida corporation, BioTissue Ocular Inc., a Florida corporation, and BioTissue Surgical Inc., a Delaware corporation (each a “Grantor” and, collectively, the “Grantors”), in favor of U.S. Bank Trust Company, National Association, not individually, but solely in its capacity as collateral agent (the “Collateral Agent”), not individually, but solely in its capacity as Collateral Agent for the Lenders (as defined below) (together with its successors and assigns in such capacity, the “Secured Party”) for the benefit of itself and the Lenders (as hereinafter defined).

### RECITALS:

WHEREAS, pursuant to that certain Credit Agreement, dated as of the date hereof (as amended, supplemented, amended and restated or otherwise modified from time to time, the “Credit Agreement”), by and among the Grantors, as Borrowers, the financial institutions from time to time party to the Credit Agreement as lenders (collectively, with their permitted successors and assignees, the “Lenders”), and the Secured Party, the Lenders have agreed to provide certain financial accommodations to the Borrowers; and

WHEREAS, the Lenders are willing to extend financial accommodations to the Borrowers as provided for in the Credit Agreement, but only upon the condition, among others, that the Grantors shall have executed and delivered to the Secured Party, for its benefit and the benefit of itself and the Lenders, this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

#### Section 1. Defined Terms; Rules of Construction.

(a) Capitalized terms used in this Agreement but not otherwise defined herein have the meanings given to them in the Credit Agreement, and if not defined therein, in the Security Agreement (as defined in the Credit Agreement, the “Security Agreement”).

(b) When used herein the following terms shall have the following meanings:

“Borrowers” shall have the meaning provided thereto in the Credit Agreement.

“Copyrights” shall have the meaning provided thereto in the Security Agreement.

“Copyright Licenses” means all agreements pursuant to which any Grantor is a licensor or licensee, granting any right under any Copyright, including but not limited to, rights to manufacture, reproduce, display, distribute, perform, modify or otherwise exploit, and sell materials embodying or derived from, any copyrighted work.

“Excluded Assets” shall have the meaning provided thereto in the Security Agreement.

“Intellectual Property” shall have the meaning provided thereto in the Security Agreement.

“Obligations” shall have the meaning provided thereto in the Credit Agreement.

“PTO” means the United States Patent and Trademark Office and any successor office or agency.

“Patents” shall have the meaning provided thereto in the Security Agreement.

“Patent Licenses” means all agreements pursuant to which any Grantor is a licensor or licensee, granting any right to manufacture, have made, import, use, or sell any invention covered in whole or in part by a Patent.

“Proceeds” shall have the meaning provided thereto in the Security Agreement.

“Products” shall have the meaning provided thereto in the Credit Agreement.

“Trademarks” shall have the meaning provided thereto in the Security Agreement.

“Trademark Licenses” mean all agreements pursuant to which any Grantor is a licensor or licensee, granting any right to use a Trademark.

“UCC” shall have the meaning provided thereto in the Security Agreement.

- (c) All Schedules, Addenda, Annexes and Exhibits hereto or expressly identified to this Agreement are incorporated herein by reference and taken together with this Agreement constitute but a single agreement. The words “herein”, “hereof” and “hereunder” or other words of similar import refer to this Agreement as a whole, including the Exhibits, Addenda, Annexes and Schedules thereto, as the same may be from time to time amended, modified, restated or supplemented, and not to any particular section, subsection or clause contained in this Agreement. Wherever from the context it appears appropriate, each term stated in either the singular or plural shall include the singular and the plural, and pronouns stated in the masculine, feminine or neuter gender shall include the masculine, the feminine and the neuter. The term “or” is not exclusive. The term “including” (or any form thereof) shall not be limiting or exclusive. All references to statutes and related regulations shall include any amendments of same and any successor statutes and regulations. All references in this Agreement or in the Schedules, Addenda, Annexes and Exhibits to this Agreement to sections, schedules, disclosure schedules, exhibits, and attachments shall refer to the corresponding sections, schedules, disclosure schedules, exhibits, and attachments of or to this Agreement. All references to any instruments or agreements, including references to any of this Agreement, the Credit Agreement or the other Loan Documents shall include any and all modifications or amendments thereto and any and all extensions or renewals thereof.

- (d) The parties acknowledge that each party and its counsel have reviewed this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement or any amendments, schedules or exhibits thereto.

Section 2. Grant of Security Interest in Intellectual Property Collateral. To secure the prompt payment to the Lenders of the Obligations now or hereafter existing from time to time, each Grantor hereby pledges and grants to the Secured Party, for its benefit and the benefit of the Lenders, a continuing security interest in and Lien upon all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Collateral"):

- (a) Trademarks and Trademark Licenses to which it is a party, including those Trademarks and exclusive Trademark Licenses referred to on Schedule I hereto;
- (b) Patents and Patent Licenses to which it is a party, including those Patents and exclusive Patent Licenses referred to on Schedule II hereto;
- (c) Copyrights and Copyright Licenses to which it is a party, including those Copyrights and exclusive Copyright Licenses referred to on Schedule III hereto;
- (d) Intellectual Property not covered by the foregoing, including those referred to on Schedule IV hereto;
- (e) Renewals, reissues, continuations, divisions, or extensions of any of the foregoing;
- (f) Rights to sue third parties for past, present or future infringement, dilution, misappropriation, or other violation of rights in any Intellectual Property, including injury to the goodwill associated with any Trademark, and all causes of action for the same; and
- (g) All products and Proceeds of all or any of the foregoing, tort claims and all claims and other rights to payment including (i) insurance claims against third parties for loss of, damage to, or destruction of, the foregoing Collateral and (ii) payments due or to become due under licenses of any or all of the foregoing and Proceeds payable under, or unearned premiums with respect to policies of insurance in whatever form; provided, however, that the Collateral shall not constitute a grant of a security interest in any trademark or service mark applications filed in the PTO on the basis of any Grantor's intent to use such trademark or service mark, unless and until a statement of use or amendment to allege use is filed in the PTO, in which event, such trademark or service mark shall automatically be included in the Collateral.

Notwithstanding anything to the contrary in this Agreement, the term "Collateral" shall be deemed to exclude all Excluded Assets, including any intent-to-use trademark applications filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. §1051, to the extent that, and solely during the period in which, the grant of a

security interest therein otherwise invalidate a Grantor's right, title or interest therein.

Section 3. Representations and Warranties. Each Grantor represents and warrants to the Secured Party, in addition to the representations and warranties in the Credit Agreement and the other Loan Documents, that this Agreement, together with the Security Agreement, is effective to create a valid security interest in favor of the Secured Party, for its benefit and the benefit of the Lenders, in all of such Grantor's Collateral. Upon (i) the filing of this Agreement in the United States Copyright Office (with respect to the Copyrights set forth on Schedule III hereto registered with the United States Copyright Office), (ii) the filing of all appropriate UCC-1 financing statements (with respect to each Grantor's (A) Patents, (B) Trademarks and (C) any Copyrights of such Grantor not registered with the United States Copyright Office) and (iii) the filing of this Agreement in the PTO (with respect to the Patents set forth on Schedule II hereto that have been granted by the PTO and the Trademarks set forth on Schedule I hereto that are registered with the PTO), such security interest will be enforceable as such as against any and all creditors of, and purchasers from, such Grantor (subject only to Permitted Liens) and all action necessary to perfect such security interest in such Collateral shall have been taken.

Section 4. Credit Agreement and Security Agreement. The security interests granted pursuant to this Agreement are granted in conjunction with the security interests granted by each Grantor to the Secured Party, for its benefit and the benefit of the Lenders, pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Secured Party with respect to the Collateral made and granted herein are more fully set forth in the Credit Agreement and the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. Any rights and remedies set forth herein are without prejudice to, and in addition to, those set forth in the Credit Agreement and the Security Agreement. In the event any provisions contained herein expressly conflict with any provisions in the Credit Agreement or the Security Agreement covering Intellectual Property, the provisions herein shall control.

The Secured Party, subject to the provisions of Section 9 of the Credit Agreement, including receipt of indemnification or security satisfactory to Agent, shall act (or omit to act) at the direction of the Required Lenders under any provision of this Agreement requiring the Secured Party to take action or to omit from taking action (other than ordinary administration) or to exercise discretion.

Section 5. Reinstatement. This Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against any Grantor for liquidation or reorganization, should any Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of such Grantor's assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a "voidable preference," "fraudulent conveyance," or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be

reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

Section 6. Notices. All notices hereunder shall be in writing (including facsimile transmission) and shall be sent to the applicable party (i) in the case of the Grantors, in care of the Borrowers, at the address of the Borrowers set forth in the Credit Agreement, and (ii) in the case of the Secured Party, at the address of the Agent set forth in the Credit Agreement, or, in each case, at such other address as such party may, by written notice received by the other parties, have designated as its address for such purpose. All notices and other communications given to any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of receipt if received during the recipient's normal business hours. Any party hereto may change its address or facsimile number or email address for notices and other communications hereunder by written notice to the other parties hereto.

Section 7. Termination of this Agreement. This Agreement shall be subject to Section 4.12 of the Security Agreement, which is hereby incorporated herein by reference *mutatis mutandis*.

Section 8. Governing Law. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS AGREEMENT SHALL BE GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW PROVISION OR RULE (WHETHER OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEW YORK.

Section 9. Counterparts; Electronic Signatures. This Agreement may be executed in any number of counterparts and by the different parties hereto on separate counterparts and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Agreement. Receipt by facsimile or electronic transmission (including PDF) of any executed signature page to this Agreement shall constitute effective delivery of such signature page. The words "delivery," "execute," "execution," "signed," "signature," and words of like import in this Agreement or any other document executed in connection herewith shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Secured Party, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary, the Secured Party is under no obligation to agree to accept electronic signatures in any form or in any format unless expressly agreed to by the Secured Party pursuant to procedures approved by it; provided, further, without limiting the foregoing, upon the reasonable request of the Secured Party, any electronic signature shall be promptly followed by such manually executed counterpart. All notices, approvals, consents, requests and any communications hereunder must be in writing and in English (provided that any such communication sent to the Secured Party hereunder must be in the form of a document that is signed manually or by way of a digital



signature provided by DocuSign (or such other digital signature provider as specified in writing to the Secured Party by the authorized representative). The Grantors each agree to assume all risks arising out of the use of digital signatures and electronic methods to submit communications to the Secured Party, including without limitation the risk of the Secured Party acting on unauthorized instructions, and the risk of interception and misuse by third parties. For the avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance by the Secured Party of a manually signed paper document, amendment, approval, consent, information, notice, certificate, request, statement, disclosure or authorization related to this Agreement (each a "Communication") which has been converted into electronic form (such as scanned into PDF format), or an electronically signed Communication converted into another format, for transmission, delivery and/or retention. Each Grantor hereby acknowledges the receipt of a copy of this Agreement. The Secured Party may, on behalf of each Grantor, create a microfilm or optical disk or other electronic image of this Agreement. The Secured Party may store the electronic image of this Agreement in its electronic form and then destroy the paper original as part of the Secured Party's normal business practices, with the electronic image deemed to be an original and of the same legal effect, validity and enforceability as the paper originals.

*[Signature Pages Follow]*

IN WITNESS WHEREOF, each Grantor has executed this Intellectual Property Security Agreement as of the date first written above.

BIOTISSUE HOLDINGS INC.

By: 

Name: Michael Cornelius  
Title: Chief Financial Officer

BIOTISSUE OCULAR INC.

By: 

Name: Michael Cornelius  
Title: Chief Financial Officer


BIOTISSUE SURGICAL INC.

By: 

Name: Michael Cornelius  
Title: Chief Financial Officer

ACCEPTED and ACKNOWLEDGED by:

U.S BANK TRUST COMPANY, NATIONAL  
ASSOCIATION, as Collateral Agent

By: 

Name: Aaron X. Smith

Title: Vice President

Schedule I  
Trademarks and Trademark Licenses


Owner	Country	Mark	Appl. No.	Filing Date	Reg. No.	Reg. Date
Bio-Tissue, Inc. <sup>1</sup>	US	AMNIOGRAFT	78146610	7/23/2002	2841984	5/11/2004
TissueTech, Inc. <sup>2</sup>	US	AMNIOGRAFT	88730168	12/17/2019	6777086	7/5/2022
TissueTech, Inc.	US	AMNIOGUARD	85865795	3/4/2013	4527971	5/13/2014
TissueTech, Inc.	US	BIOTISSUE	97588024	9/12/2022	-	-
TissueTech, Inc.	US	BIOTISSUE	77134634	3/19/2007	3363953	1/1/2008
BioTissue Holdings Inc.	US	CAM360 AMNIOGRAFT	98322150	12/19/2023	-	-
Amniox Medical, Inc. <sup>3</sup>	US	CLARIX	85666841	7/2/2012	4515363	4/15/2014
TissueTech, Inc.	US	CORD 1K	86294384	5/29/2014	4667121	1/6/2015
TissueTech, Inc.	US	CRYOTEK	85750442	10/10/2012	4522781	4/29/2014
TissueTech, Inc.	TW	CRYOTEK	108083052	12/18/2019	02099774	11/16/2020

<sup>1</sup> Now known as BioTissue Ocular Inc.

<sup>2</sup> Now known as BioTissue Holdings Inc.

<sup>3</sup> Now known as BioTissue Surgical Inc.

Amniox Medical, Inc.	US	NEOX	85531160	2/1/2012	4205381	9/11/2012
Bio-Tissue, Inc.	US	PROKERA	77134622	3/19/2007	3347610	12/4/2007
TissueTech, Inc.	EUTM	PROKERA	15314181	4/6/2016	15314181	3/11/2017
TissueTech, Inc.	TW	PROKERA	106073651	11/22/2017	001977710	4/1/2019
TissueTech, Inc.	UK	PROKERA	UK00915314181	4/6/2016	UK00915314181	3/11/2017
TissueTech, Inc.	US	RECRYVIA	90590617	3/19/2021	-	-
TissueTech, Inc.	US	REGENESOL	87133643	8/10/2016	5556306	9/4/2018
TissueTech, Inc.	EUTM	REGENESOL	16343899	2/9/2017	16343899	6/6/2017
TissueTech, Inc.	UK	REGENESOL	UK00916343899	2/9/2017	UK00916343899	6/6/2017
TissueTech, Inc.	US	RESPINA	87192744	10/4/2016	5481836	5/29/2018
TissueTech, Inc.	US	SHARING MIRACLES	90521245	2/9/2021	7157931	9/5/2023
TissueTech, Inc.	US	STERITEK	86983256	10/5/2015	5360643	12/19/2017
TissueTech, Inc.	US	TISSUETECH	88138543	10/1/2018	5917974	11/26/2019
TissueTech, Inc.	TW	TISSUETECH	108083050	12/18/2019	02070194	7/1/2020
TissueTech, Inc.	TW	TTAX-01	109022178	4/9/2020	02117786	2/1/2021
TissueTech, Inc.	US	BioTissue Logo	97588029	9/12/2022	-	-

Amniox Medical, Inc.	US		85531192	2/1/2012	4205384	9/11/20012
----------------------	----	---	----------	----------	---------	------------

**Schedule II**  
**Patents and Patent Licenses**

Owner	Application Number	Country	Status	Application Title	Filing Date	Patent Number	Issue Date
BioTissue Holding Inc.	105115893	TW	Granted	COMPOSITIONS AND METHODS FOR PREVENTING THE PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION OF EPITHELIAL CELLS	20-May-2016	1720984	11-Mar-2021
BioTissue Holding Inc.	16/421191	US	ISSUED	COMPOSITIONS AND METHODS FOR PREVENTING THE PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION OF EPITHELIAL CELLS	23-May-2019	11318169	03-May-2022
BioTissue Holding Inc.	15/160487	US	ISSUED	COMPOSITIONS AND METHODS FOR PREVENTING THE PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION OF EPITHELIAL CELLS	20-May-2016	10342831	09-Jul-2019
BioTissue Holding Inc.	16/591219	US	ISSUED	APPARATUSES AND METHODS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS	02-Oct-2019	11590265	28-Feb-2023

BioTissue Holding Inc.	15/727445	US	ISSUED	COMPOSITIONS OF MORSELIZED UMBILICAL CORD AND/OR AMNIOTIC MEMBRANE AND METHODS OF USE THEREOF	06-Oct-2017	11116800	14-Sep-2021
BioTissue Holding Inc.	14/729489	US	ISSUED	COMPOSITIONS OF MORSELIZED UMBILICAL CORD AND/OR AMNIOTIC MEMBRANE AND METHODS OF USE THEREOF	03-Jun-2015	9808491	07-Nov-2017
BioTissue Holding Inc.	16/063025	US	ISSUED	FETAL SUPPORT TISSUE PRODUCTS AND METHODS OF USE	15-Jun-2018	11707492	25-Jul-2023
BioTissue Holding Inc.	15111254.1	HK	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	1210425	02-Jun-2022
BioTissue Holding Inc.	14/414047	US	ISSUED	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	09-Jan-2015	10040821	07-Aug-2018
BioTissue Holding Inc.	10-2015-7003180	KR	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	10-22236805	31-Mar-2021
BioTissue Holding Inc.	2016-147710	JP	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	6472142	01-Feb-2019
BioTissue Holding Inc.	869/DELNP/2015	IN	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	364137	06-Apr-2021
BioTissue Holding Inc.	201380047367.2	CN	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	ZL201380047367.2	18-Feb-2022
BioTissue Holding Inc.	13745221.5	IT	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	2872181	18-Nov-2020

TissueTech, Inc.	13745221.5	ES	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	2872181	18-Nov-2020
TissueTech, Inc.	13745221.5	GB	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	2872181	18-Nov-2020
TissueTech, Inc.	13745221.5	FR	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	2872181	18-Nov-2020
TissueTech, Inc.	13745221.5	DE	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	2872181	18-Nov-2020
TissueTech, Inc.	13745221.5	EP	Granted	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013	2872181	18-Nov-2020
TissueTech, Inc.	16/898309	US	ISSUED	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jun-2020	11518782	06-Dec-2022
TissueTech, Inc.	16/274123	US	ISSUED	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	12-Feb-2019	10717763	21-Jul-2020
TissueTech, Inc.	15/214706	US	ISSUED	COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	20-Jul-2016	10253065	09-Apr-2019
TissueTech, Inc.	13/782968	US	ISSUED	METHODS OF ISOLATING AND CULTURING STEM CELLS	01-Mar-2013	8940294	27-Jan-2015
TissueTech, Inc.	14/240712	US	ISSUED	METHODS OF STERILIZING FETAL SUPPORT TISSUES	14-May-2014	9931423	03-Apr-2018

TRADEMARK

REEL: 008470 FRAME: 0129



TissueTech, Inc.	2844115	CA	Granted	METHODS OF STERILIZING FETAL SUPPORT TISSUES	24-Aug-2012	2844115	23-Nov-2021
BioTissue Holding Inc.	14/819319	US	ISSUED	METHODS OF STERILIZING FETAL SUPPORT TISSUES	05-Aug-2015	9682160	20-Jun-2017
BioTissue Holding Inc.	14/125301	US	ISSUED	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF	11-Apr-2014	9682044	20-Jun-2017
TissueTech, Inc.	12796366.8	IT	Granted	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF	08-Jun-2012	2717888	09-Sep-2020
TissueTech, Inc.	12796366.8	ES	Granted	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF	08-Jun-2012	2717888	09-Sep-2020
TissueTech, Inc.	12796366.8	GB	Granted	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF	08-Jun-2012	2717888	09-Sep-2020
TissueTech, Inc.	12796366.8	FR	Granted	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF	08-Jun-2012	2717888	09-Sep-2020
TissueTech, Inc.	12796366.8	DE	Granted	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF	08-Jun-2012	2717888	09-Sep-2020
TissueTech, Inc.	12796366.8	EP	Granted	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT TISSUE POWDER PRODUCTS, AND USES THEREOF	08-Jun-2012	2717888	09-Sep-2020
BioTissue	15/609809	US	ISSUED	METHODS OF PROCESSING FETAL SUPPORT TISSUES, FETAL SUPPORT	31-May-2017	10426731	01-Oct-2019

Holdings Inc.				TISSUE POWDER PRODUCTS, AND USES THEREOF				
BioTissue Holding Inc.	14/004992	US	ISSUED	METHODS OF MODULATING BONE REMODELING	31-Dec-2013	9526770		27-Dec-2016
BioTissue Holding Inc.	15/348736	US	ISSUED	METHODS OF MODULATING BONE REMODELING	10-Nov-2016	9675733		13-Jun-2017
TissueTech Inc.	2771908	CA	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	2771908		21-May-2019
TissueTech Inc.	16162822.7	ES	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	3061468		09-Oct-2019
TissueTech Inc.	10815849.4	ES	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	10815849		09-Oct-2019
TissueTech Inc.	16162822.7	GB	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	3061468		09-Oct-2019
TissueTech Inc.	10815849.4	GB	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	2470231		09-Oct-2019
TissueTech Inc.	16162822.7	FR	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	3061468		09-Oct-2019
TissueTech Inc.	10815849.4	FR	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	2470231		09-Oct-2019
TissueTech Inc.	16162822.7	DE	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	3061468		09-Oct-2019

TissueTech, Inc.	10815849.4	DE	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	6020100614 63.8	09-Oct-2019
TissueTech, Inc.	16162822.7	EP	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	3061468	09-Oct-2019
TissueTech, Inc.	10815849.4	EP	Granted	UMBILICAL CORD AMNIOTIC MEMBRANE PRODUCTS	25-Aug-2010	2470231	09-Oct-2019
BioTissue Holding Inc.	12/446740	US	ISSUED	RNAI METHODS AND COMPOSITIONS FOR STIMULATING PROLIFERATION OF CELLS WITH ADHERENT JUNCTIONS	21-Jul-2009	9006192	14-Apr-2015
BioTissue Holding Inc.	10/472117	US	ISSUED	AMNIOTIC MEMBRANE COVERING FOR A TISSUE SURFACE AND DEVICES FACILITATING FASTENING OF MEMBRANES	19-Apr-2004	7494802	24-Feb-2009
BioTissue Holding Inc.	06804232.4	EP	Granted	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND METHODS OF USE	27-Sep-2006	1933852	19-Dec-2018
BioTissue Holding Inc.	15/636227	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION	28-Jun-2017	10272119	30-Apr-2019
BioTissue Holding Inc.	14/880135	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-ANGIOGENESIS TREATMENT	09-Oct-2015	9750772	05-Sep-2017
BioTissue Holding Inc.	14/848153	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-INFLAMMATION METHODS	08-Sep-2015	9750771	05-Sep-2017
BioTissue Holding Inc.	14/848148	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED	08-Sep-2015	9724370	08-Aug-2017

Holdings Inc.				COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION				
BioTissue Holdings Inc.	14/848143	US	ISSUED	PURIFIED AMNIOTIC MEMBRANE COMPOSITIONS AND METHODS OF USE	08-Sep-2015	9956252	01-May-2018	
BioTissue Holdings Inc.	13/802447	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-INFLAMMATION METHODS	13-Mar-2013	9161956	20-Oct-2015	
BioTissue Holdings Inc.	13/802359	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION	13-Mar-2013	9161955	20-Oct-2015	
BioTissue Holdings Inc.	13/802264	US	ISSUED	PURIFIED AMNIOTIC MEMBRANE COMPOSITIONS AND METHODS OF USE	13-Mar-2013	9198939	01-Dec-2015	
BioTissue Holdings Inc.	13/796761	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-ANGIOGENESIS TREATMENT	12-Mar-2013	9161954	20-Oct-2015	
BioTissue Holdings Inc.	13/453840	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-ANGIOGENESIS TREATMENT	23-Apr-2012	8420126	16-Apr-2013	
BioTissue Holdings Inc.	13/453771	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-INFLAMMATION METHODS	23-Apr-2012	8455009	04-Jun-2013	
BioTissue Holdings Inc.	13/453765	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION	23-Apr-2012	8440235	14-May-2013	

BioTissue Holding s Inc.	13/438759	US	ISSUED	PURIFIED AMNIOTIC MEMBRANE COMPOSITIONS AND METHODS OF USE	03-Apr-2012	8460714	11-Jun-2013
BioTissue Holding s Inc.	11/529658	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI-INFLAMMATION METHODS	27-Sep-2006	8182841	22-May-2012
BioTissue Holding s Inc.	11/528902	US	ISSUED	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION	27-Sep-2006	8182840	22-May-2012
BioTissue Holding s Inc.	11/528980	US	ISSUED	PURIFIED AMNIOTIC MEMBRANE COMPOSITIONS AND METHODS OF USE	27-Sep-2006	8153162	10-Apr-2012
BioTissue Holding s Inc.	63/459,162	US	Pending	<i>[Unknown/not publically available]</i>	13-Apr-2023		
BioTissue Holding s Inc.	112115161	TW	Pending	COMPOSITIONS AND METHODS RELATING TO POOLED FETAL SUPPORT TISSUE	24-Apr-2023		
BioTissue Holding s Inc.	PCT/US2023/019602	WO	Published	COMPOSITIONS AND METHODS RELATING TO POOLED FETAL SUPPORT TISSUE	24-Apr-2023		
BioTissue Holding s Inc.	110139738	TW	Published	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	26-Oct-2021		
BioTissue Holding s Inc.	18/033,470	US	Published	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	24-Apr-2023		

TRADEMARK

REEL: 008470 FRAME: 0134

BioTiss ue Holding s Inc.	10-2023- 7017848	KR	Published	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	25-Oct-2021		
BioTiss ue Holding s Inc.	2023- 549964	JP	Published	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	25-Oct-2021		
BioTiss ue Holding s Inc.	20218008 7550.X	CN	Published	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	25-Oct-2021		
BioTiss ue Holding s Inc.	3196485	CA	Published	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	25-Oct-2021		
BioTiss ue Holding s Inc.	20213709 54	AU	Pending	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	25-Oct-2021		
BioTiss ue Holding s Inc.	21887281. 0	EP	Published	METHODS FOR PROCESSING FETAL SUPPORT TISSUE	25-Oct-2021		
BioTiss ue Holding s Inc.	62023072 938.1	HK	Published	METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS	2-Apr-2021		
BioTiss ue Holding s Inc.	17/914691	US	Published	METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS	26-Sep- 2022		
BioTiss ue Holding s Inc.	2022- 559476	JP	Published	METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS	2-Apr-2021		

BioTiss ue Holding s Inc.	20218004 0612.1	CN	Published	METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS	2-Apr-2021		
BioTiss ue Holding s Inc.	21778873. 6	EP	Published	METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS	2-Apr-2021		
BioTiss ue Holding s Inc.	62022062 230.7	HK	Published	METHODS OF PROMOTING VASCULOGENESIS	19-Jun-2020		
BioTiss ue Holding s Inc.	17/620650	US	Published	METHODS OF PROMOTING VASCULOGENESIS	17-Dec- 2021		
BioTiss ue Holding s Inc.	20208005 9168.3	CN	Published	METHODS OF PROMOTING VASCULOGENESIS	19-Jun-2020		
BioTiss ue Holding s Inc.	3144419	CA	Published	METHODS OF PROMOTING VASCULOGENESIS	19-Jun-2020		
BioTiss ue Holding s Inc.	20825845. 9	EP	Published	METHODS OF PROMOTING VASCULOGENESIS	19-Jun-2020		
BioTiss ue Holding s Inc.	62022045 726.6	HK	Published	METHODS OF CELLULAR REPROGRAMMING	6-Nov-2019		
BioTiss ue Holding s Inc.	17/291070	US	Published	METHODS OF CELLULAR REPROGRAMMING	4-May-2021		

BioTiss ue Holding s Inc.	20198008 8142.9	CN	Published	METHODS OF CELLULAR REPROGRAMMING	6-Nov-2019		
BioTiss ue Holding s Inc.	3117723	CA	Published	METHODS OF CELLULAR REPROGRAMMING	6-Nov-2019		
BioTiss ue Holding s Inc.	19881805. 6	EP	Published	METHODS OF CELLULAR REPROGRAMMING	6-Nov-2019		
BioTiss ue Holding s Inc.	62023070 257.8	HK	Published	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	12-Feb- 2021		
BioTiss ue Holding s Inc.	17/798421	US	Published	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	9-Aug-2022		
BioTiss ue Holding s Inc.	10-2022- 7031259	KR	Published	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	12-Feb- 2021		
BioTiss ue Holding s Inc.	2022- 548856	JP	Published	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	12-Feb- 2021		
BioTiss ue Holding s Inc.	20218002 8053.2	CN	Published	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	12-Feb- 2021		
BioTiss ue Holding s Inc.	3170323	CA	Published	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	12-Feb- 2021		



BioTiss ue Holding s Inc.	20212197 72	AU	Pending	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	12-Feb- 2021		
BioTiss ue Holding s Inc.	21753538. 4	EP	Published	METHODS OF KILLING OR INHIBITING THE GROWTH OF CANCEL CELLS	12-Feb- 2021		
BioTiss ue Holding s Inc.	17/675887	US	Published	COMPOSITIONS AND METHODS FOR PREVENTING THE PROLIFERATION AND EPITHELIAL-MESENCHYMAL TRANSITION OF EPITHELIAL CELLS	18-Feb- 2022		
BioTiss ue Holding s Inc.	18/100696	US	Published	APPARATUSES AND METHODS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS	24-Jan-2023		
BioTiss ue Holding s Inc.	17104113. 5	HK	Published	COMPOSITIONS OF MORSELIZED UMBILICAL CORD AND/OR AMNIOTIC MEMBRANE AND METHODS OF USE THEREOF	3-Jun-2015		
BioTiss ue Holding s Inc.	20158002 9838.6	CN	Published	COMPOSITIONS OF MORSELIZED UMBILICAL CORD AND/OR AMNIOTIC MEMBRANE AND METHODS OF USE THEREOF	3-Jun-2015		
BioTiss ue Holding s Inc.	17/341296	US	Published	COMPOSITIONS OF MORSELIZED UMBILICAL CORD AND/OR AMNIOTIC MEMBRANE AND METHODS OF USE THEREOF	7-Jun-2021		
BioTiss ue Holding s Inc.	18/201119	US	Published	FETAL SUPPORT TISSUE PRODUCTS AND METHODS OF USE	23-May- 2023		
BioTiss ue Holding s Inc.	20221028 4199.X	CN	Published	COMPOSITIONS CONTAINING HC- HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013		

TRADEMARK

REEL: 008470 FRAME: 0138

BioTiss ue Holding s Inc.	2878163	CA	Published	COMPOSITIONS CONTAINING HC- HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013		
BioTiss ue Holding s Inc.	2028234.3	EP	Published	COMPOSITIONS CONTAINING HC- HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	10-Jul-2013		
BioTiss ue Holding s Inc.	18/051796	US	Published	COMPOSITIONS CONTAINING HC- HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF	1-Nov-2022		
BioTiss ue Holding s Inc.	3133869	CA	Published	METHODS OF STERILIZING FETAL SUPPORT TISSUES	24-Aug- 2012		
BioTiss ue Holding s Inc.	15/588331	US	Published	METHODS OF MODULATING BONE REMODELING	5-May-2017		
BioTiss ue Holding s Inc.	18/133961	US	Published	UMBILICAL CORD PRODUCTS	12-Apr- 2023		
BioTiss ue Holding s Inc.	18/642534	US	Pending	COMPOSITIONS AND METHODS RELATING TO POOLED FETAL SUPPORT TISSUE	22-Apr- 2024		
BioTiss ue Holding s Inc.	11/535924	US	Issued	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND ANTI- ANGIOGENESIS TREATMENT	27-Sep- 2026	8187639	29-May-2012
BioTiss ue Holding s Inc.	17104113. 5	HK	Pending	COMPOSITIONS AND METHODS	03-Jun-2015		

TRADEMARK

REEL: 008470 FRAME: 0139

BioTissue Holding s Inc.	20151020 9392.7	CN	Issued	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND METHODS OF USE	27-Sep-2006	ZL2015102 09392.7	23-Apr-2019
BioTissue Holding s Inc.	20068004 4389.3	CN	Issued	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND METHODS OF USE	27-Sep-2006	ZL2006800 44389.3	03-Jun-2015
BioTissue Holding s Inc.	15/879042	US	Issued	AMNIOTIC MEMBRANE PREPARATIONS AND PURIFIED COMPOSITIONS AND THERAPY FOR SCAR REVERSAL AND INHIBITION	24-Jan-2018	10632155	28-Apr-2020

**Schedule III**

**Copyrights and Copyright Licenses**

None.

**Schedule IV**

**Other Intellectual Property - Domains**

1. BioTissue.com
2. TissueTech.com